C-(2-methyl-2-aza-bicyclo[2.2.2]oct-1-yl)-C-phenyl-methylamine | 1108615-74-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: C-(2-methyl-2-aza-bicyclo[2.2.2]oct-1-yl)-C-phenyl-methylamine
• 英文别名: (2-methyl-2-azabicyclo[2.2.2]octan-1-yl)(phenyl)methanamine；(2-methyl-2-azabicyclo[2.2.2]octan-1-yl)-phenylmethanamine
• CAS: 1108615-74-2
• 化学式: C₁₅H₂₂N₂
• 分子量: 230.353
• InChiKey: MENFTLSARDASLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,4-二氯苯甲酸 、 C-(2-methyl-2-aza-bicyclo[2.2.2]oct-1-yl)-C-phenyl-methylamine 在 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 二异丙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以90%的产率得到2,4-dichloro-N-((2-methyl-2-azabicyclo[2.2.2]octan-1-yl)(phenyl)methyl)benzamide
  参考文献：
  名称：

  Novel Compounds 894

  摘要：

  该发明涉及2-aza-bicyclo[2.2.2]辛烷化合物及其用途。特别是该发明涉及这些化合物及其在治疗精神分裂症等疾病、障碍或症状中的药用用途。

  公开号：

  US20090030033A1
• 作为产物：
  描述：

  在 盐酸 、 二苯基硅烷 、 H(Rh)(CO)(PPh₃)₃ 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 为溶剂， 生成 C-(2-methyl-2-aza-bicyclo[2.2.2]oct-1-yl)-C-phenyl-methylamine
  参考文献：
  名称：

  Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1

  摘要：

  A series of isoquinuclidine benzamides as glycine uptake inhibitors for the treatment of schizophrenia are described. Potency, lipophilicity, and intrinsic human microsomal clearance were parameters for optimization. Potency correlated with the nature of the ortho substituents of the benzamide ring, and reductions in lipophilicity could be achieved through heteroatom incorporation in the benzamide and pendant phenyl moieties. Improvements in human CLint were achieved through changes in ring size and the N-alkyl group of the isoquinuclidine itself, with des-alkyl derivatives (40-41, 44) demonstrating the most robust microsomal stability. Dimethylbenzamide 9 was tested in a mouse MK801 LMA assay and had a statistically significant attenuation of locomotor activity at 3 and 10 mu mol/kg compared to control. (C) 2018 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2018.02.029

文献信息

• [EN] 2-AZA-BICYCLO[2.2.2]OCTANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS 2-AZA-BICYCLO[2.2.2]OCTANE ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2010087761A1

  公开（公告）日：2010-08-05

  This invention relates to 2-aza-bicyclo [2.2.2] octane compounds (and salts thereof), the process for making such a compound and pharmaceutical compositions comprising such a compound. The invention also relates to the use of the compounds for modulating the glycine transporter 1 (GIyTl) and for the treatment of psychosis, cognitive disorders, bipolar disorders, depression disorders, anxiety disorders, posttraumatic stress disorders and pain.

  这项发明涉及2-aza-bicyclo [2.2.2]辛烷化合物（及其盐），制备这种化合物的过程以及包含这种化合物的药物组合物。该发明还涉及利用这些化合物调节甘氨酸转运蛋白1（GIyTl）并用于治疗精神病、认知障碍、双相情感障碍、抑郁症、焦虑症、创伤后应激障碍和疼痛。
• [EN] 2-AZABICYCLO(2.2.2)OCTANE DERIVATIVES AS MODULATORS OF THE GLYCINE TRANSPORTER I RECEPTOR<br/>[FR] DÉRIVÉS DE 2-AZABICYCLO(2,2,2)OCTANE EN TANT QUE MODULATEURS DU RÉCEPTEUR TRANSPORTEUR DE TYPE I DE LA GLYCINE
  申请人：ASTRAZENECA AB

  公开号：WO2009013535A1

  公开（公告）日：2009-01-29

  The invention relates to 2-aza-bicyclo[2.2.2]octane compounds and uses thereof. Particularly the invention relates to such compounds and their uses as pharmaceuticals in treating pyshoses such as schizophrenia and other diseases, disorders, or conditions.

  本发明涉及2-aza-bicyclo[2.2.2]辛烷化合物及其用途。特别是本发明涉及这些化合物及其用途作为药物治疗精神分裂症和其他疾病、障碍或病况。
• Novel Compounds 894
  申请人：Albert Jeffrey Scott

  公开号：US20090030033A1

  公开（公告）日：2009-01-29

  The invention relates to 2-aza-bicyclo[2.2.2]octane compounds and uses thereof. Particularly the invention relates to such compounds and their uses as pharmaceuticals in treating pyshoses such as schizophrenia and other diseases, disorders, or conditions.

  该发明涉及2-aza-bicyclo[2.2.2]辛烷化合物及其用途。特别是该发明涉及这些化合物及其在治疗精神分裂症等疾病、障碍或症状中的药用用途。
• Bicyclo((aryl)methyl)benzamides as inhibitors of GlyT1
  作者：Jeffrey G. Varnes、Hui Xiong、Janet M. Forst、Christopher R. Holmquist、Glen E. Ernst、William Frietze、Bruce Dembofsky、Don W. Andisik、William E. Palmer、Lindsay Hinkley、Gary B. Steelman、Deidre E. Wilkins、Gaochao Tian、Gerald Jonak、William M. Potts、Xia Wang、Todd A. Brugel、Cristóbal Alhambra、Michael W. Wood、Chris A. Veale、Jeffrey S. Albert

  DOI：10.1016/j.bmcl.2018.02.029

  日期：2018.4

  A series of isoquinuclidine benzamides as glycine uptake inhibitors for the treatment of schizophrenia are described. Potency, lipophilicity, and intrinsic human microsomal clearance were parameters for optimization. Potency correlated with the nature of the ortho substituents of the benzamide ring, and reductions in lipophilicity could be achieved through heteroatom incorporation in the benzamide and pendant phenyl moieties. Improvements in human CLint were achieved through changes in ring size and the N-alkyl group of the isoquinuclidine itself, with des-alkyl derivatives (40-41, 44) demonstrating the most robust microsomal stability. Dimethylbenzamide 9 was tested in a mouse MK801 LMA assay and had a statistically significant attenuation of locomotor activity at 3 and 10 mu mol/kg compared to control. (C) 2018 Elsevier Ltd. All rights reserved.